Advancing Therapies for Patients

Find a clinical trial

For Partners

page image
shadow image

Text Size

minus image

plus image

plus image

Print

Print image

Email a Friend

Facility Fact Sheet

The Drug Development Programme of Sarah Cannon Research Institute, part of HCA Healthcare UK, offers consistent performance and excellence through a dedicated, experienced oncology drug development team, state-of-the-art clinical trials unit in central London, competitive startup timelines, and rapid patient accrual within a large referral network.

Our Facility

  • CQC-registered oncology trials unit
  • On-site pharmacy
  • PK testing facilities
  • -20 + -80° C freezers
  • Refrigerated and non-refrigerated centrifuges
  • Cardiac monitoring
  • Access to hospital-based critical care services
  • Twelve treatment chairs/beds
  • Molecular profiling capabilities 

For Patients

  • Broad clinical trials portfolio (solid and hematological malignancies)
  • Patient-centered support services and referrals
  • Private areas for treatment
  • On-site catering for patients
  • Wireless internet and individual patient
  • entertainment systems

For Partners

We are committed to our partners’ goals, and we tailor our teams and processes to meet them, ensuring strong science and consistent quality every step of the way. As collaborators, we strive to provide superior insights that contribute to discovery and success.

Our Team of Professionals

We have a fully-staffed nursing and clinical research team including:

  • Principal investigators
  • Clinical research fellows
  • Clinical trial management team
  • Quality assurance manager
  • Pharmacy team
  • Administrative office support
  • Laboratory team
  • Data entry team
  • Specialist nurses

Facility Amenities and History

  • 13,000-square-foot, purpose-designed facility
  • Registered listed historic building on Harley Street
  • Central London location serviced by three main rail stations and Tube

Study Metrics

  • More than 100 clinical trials initiated across all study phases and tumor types
  • Pre-screened more than 1,400 patients for rare mutations, amplifications or other alterations
  • More than 100 new patients are treated annually

Latest Videos

watch the latest videos.

Learn more

News

news from the industry.

Read more

hero1 image
Sarah Cannon Research UK NHS Ventures
University College London Hospitals
LOC